Skip to main content

Table 4 Grade 3–5 adverse events related to regorafenib

From: First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Adverse event

Grade 3 n (%)

Grade 4 n (%)

Grade 5 n (%)

Total (Grade3–5) n %

Hypertension

14 (30)

1 (2.1)

0

15 (32)a

Fatigue

14 (30)

0

 

14 (30)

Hypophosphatemia

6 (13)

0

0

6 (13)

HFSRa

4 (8.5)

0

0

4 (8.5)

Diarrhea

4 (8.5)

0

0

4 (8.5)

Increased AST

3 (6.4)

0

0

3 (6.4)

Increased GGT

3 (6.4)

0

0

3 (6.4)

Mucositis

3 (6.4)

0

0

3 (6.4)

Anorexia

2 (4.3)

0

0

2 (4.3)

Increased bilirubin

2 (4.3)

0

0

2 (4.3)

Increased lipase

1 (2.1)

1 (2.1)

0

2 (4.3)

Rectal bleeding

1 (2.1)

0

1 (2.1)

2 (4.3)

Hyperuricemia

0

1 (2.1)

0

1 (2.1)

Sudden death

0

0

1 (2.1)

1 (2.1)

Stroke

1 (2.1)

0

0

1 (2.1)

Pancreatitis

1 (2.1)

0

0

1 (2.1)

Stomathitis

1 (2.1)

0

0

1 (2.1)

Hyperglucemia

1 (2.1)

0

0

1 (2.1)

Skin rash

1 (2.1)

0

0

1 (2.1)

Proteinuria

1 (2.1)

0

0

1 (2.1)

Pancreatitis

1 (2.1)

0

0

1 (2.1)

Nausea

1 (2.1)

0

0

1 (2.1)

Constipation

1 (2.1)

0

0

1 (2.1)

Vaginitis

1 (2.1)

0

0

1 (2.1)

Aphonia

1 (2.1)

0

0

1 (2.1)

Somnolence

1 (2.1)

0

0

1 (2.1)

Dry mouth

1 (2.1)

0

0

1 (2.1)

Abdominal pain

1 (2.1)

0

0

1 (2.1)

Increased ALT

1 (2.1)

0

0

1 (2.1)

Tumor abscess

1 (2.1)

0

0

1 (2.1)

Pneumonia

1 (2.1)

0

0

1 (2.1)

Intestinal perforation

1 (2.1)

0

0

1 (2.1)

  1. a12 out 15 patients (89%) who experienced hypertension, presented hypertension at baseline
  2. Abbreviations: HFSR Hand Foot Skin Reaction